Pentoxifylline (Trental) injection 20mg 10 vials

Pentoxifylline (Trental) injection is a xanthine derivative. It improves the microcirculation and blood rheology. The mechanism of action associated with inhibition of phosphodiesterase, and an increase of cyclic adenosine monophosphate 3.5 (3.5 AMP) in platelets and adenosine triphosphate (ATP) in erythrocytes with simultaneous saturation of the energy potential, which in turn leads to vasodilation, reducing the total peripheral vascular resistance an increase in systolic and minute volume of blood without a significant change in heart rate. Expanding the coronary arteries, increases the delivery of oxygen to the myocardium (light antianginal effect), pulmonary vessels - improves blood oxygenation.

When administered intravenously, it leads to increased collateral circulation, increase volume of blood flowing through a unit cross section.

It reduces blood viscosity causes platelet disaggregation, increases the elasticity of red blood cells (due to the impact on pathologically altered deformability of red blood cells). It improves the microcirculation in the areas of impaired circulation.

In peripheral arterial occlusive disease ( "intermittent" claudication) leads to a lengthening of the distance away, elimination of night leg cramps and pain at rest.

It improves the microcirculation and blood rheology, has a vasodilatory effect, blocks the phosphodiesterase, and contributes to the accumulation of c-AMP in cells. Erythrocyte membrane elasticity increases, reducing their adhesion, platelet aggregation and decreases blood viscosity. Blocks adenosine receptors.

Indications:

• Peripheral circulatory disorders;
• Ischemic cerebral stroke, circulatory disorders of the brain due to atherosclerosis, encephalopathy;
• Trophic disorders of tissues and organs associated with thrombosis of arteries or veins, varicose veins, frostbite;
• Diabetic angiopathy;
• Poor circulation in the eye blood vessels;
• Disruption of the middle ear vascular origin that accompanies hearing loss.

Side effect:

The first signs of overdose: weakness, dizziness, tachycardia and low blood pressure, drowsiness development, fainting, agitation, convulsions.

Treatment is symptomatic: the maintenance or restoration of blood pressure, maintaining respiratory function.

Suggested Use:

The drug may be administered in / in / a.

B / drip slowly injected at a dose of 250-500 mg per 100 ml of isotonic sodium chloride solution or 5% glucose solution (duration of injection - 90-180 min); intraarterially - first dose of 20-50 mg per 100 ml of isotonic sodium chloride solution, and in subsequent days - 200-300 30-50 mg per ml of solvent.

Injection speed: 100 mg (5 ml of a 2% solution of pentoxifylline) for 10 min.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice - the outer box design may vary before prior notice!